The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction

Raymond J. Kim, Edwin Wu, Allen Rafael, Enn Ling Chen, Michele A. Parker, Orlando Simonetti, Francis J. Klocke, Robert O. Bonow, Robert M. Judd

Research output: Contribution to journalArticle

Abstract

Background: Recent studies indicate that magnetic resonance imaging (MRI) after the administration of contrast material can be used to distinguish between reversible and irreversible myocardial ischemic injury regardless of the extent of wall motion or the age of the infarct. We hypothesized that the results of contrast-enhanced MRI can be used to predict whether regions of abnormal ventricular contraction will improve after revascularization in patients with coronary artery disease. Methods: Gadolinium-enhanced MRI was performed in 50 patients with ventricular dysfunction before they underwent surgical or percutaneous revascularization. The transmural extent of hyperenhanced regions was postulated to represent the transmural extent of non-viable myocardium. The extent of regional contractility at the same locations was determined by cine MRI before and after revascularization in 41 patients. Results: Contrast-enhanced MRI showed hyperenhancement of myocardial tissue in 40 of 50 patients before revascularization. In all patients with hyperenhancement the difference in image intensity between hyperenhanced regions and regions without hyperenhancement was more than 6 SD. Before revascularization, 804 of the 2093 myocardial segments analyzed (38 percent) had abnormal contractility, and 694 segments (33 percent) had some areas of hyperenhancement. In an analysis of all 804 dysfunctional segments, the likelihood of improvement in regional contractility after revascularization decreased progressively as the transmural extent of hyperenhancement before revascularization increased (P<0.001). For instance, contractility increased in 256 of 329 segments (78 percent) with no hyperenhancement before revascularization, but in only 1 of 58 segments with hyperenhancement of more than 75 percent of tissue. The percentage of the left ventricle that was both dysfunctional and not hyperenhanced before revascularization was strongly related to the degree of improvement in the global mean wall-motion score (P<0.001) and the ejection fraction (P<0.001) after revascularization. Conclusions: Reversible myocardial dysfunction can be identified by contrast-enhanced MRI before coronary revascularization. (C) 2000, Massachusetts Medical Society.

Original languageEnglish (US)
Pages (from-to)1445-1453
Number of pages9
JournalNew England Journal of Medicine
Volume343
Issue number20
DOIs
StatePublished - Nov 16 2000
Externally publishedYes

Fingerprint

Magnetic Resonance Imaging
Cine Magnetic Resonance Imaging
Ventricular Dysfunction
Medical Societies
Gadolinium
Contrast Media
Heart Ventricles
Coronary Artery Disease
Myocardium
Wounds and Injuries

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kim, R. J., Wu, E., Rafael, A., Chen, E. L., Parker, M. A., Simonetti, O., ... Judd, R. M. (2000). The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. New England Journal of Medicine, 343(20), 1445-1453. https://doi.org/10.1056/NEJM200011163432003

The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. / Kim, Raymond J.; Wu, Edwin; Rafael, Allen; Chen, Enn Ling; Parker, Michele A.; Simonetti, Orlando; Klocke, Francis J.; Bonow, Robert O.; Judd, Robert M.

In: New England Journal of Medicine, Vol. 343, No. 20, 16.11.2000, p. 1445-1453.

Research output: Contribution to journalArticle

Kim, RJ, Wu, E, Rafael, A, Chen, EL, Parker, MA, Simonetti, O, Klocke, FJ, Bonow, RO & Judd, RM 2000, 'The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction', New England Journal of Medicine, vol. 343, no. 20, pp. 1445-1453. https://doi.org/10.1056/NEJM200011163432003
Kim, Raymond J. ; Wu, Edwin ; Rafael, Allen ; Chen, Enn Ling ; Parker, Michele A. ; Simonetti, Orlando ; Klocke, Francis J. ; Bonow, Robert O. ; Judd, Robert M. / The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. In: New England Journal of Medicine. 2000 ; Vol. 343, No. 20. pp. 1445-1453.
@article{ecca8317015641eb90c7f598f9342f82,
title = "The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction",
abstract = "Background: Recent studies indicate that magnetic resonance imaging (MRI) after the administration of contrast material can be used to distinguish between reversible and irreversible myocardial ischemic injury regardless of the extent of wall motion or the age of the infarct. We hypothesized that the results of contrast-enhanced MRI can be used to predict whether regions of abnormal ventricular contraction will improve after revascularization in patients with coronary artery disease. Methods: Gadolinium-enhanced MRI was performed in 50 patients with ventricular dysfunction before they underwent surgical or percutaneous revascularization. The transmural extent of hyperenhanced regions was postulated to represent the transmural extent of non-viable myocardium. The extent of regional contractility at the same locations was determined by cine MRI before and after revascularization in 41 patients. Results: Contrast-enhanced MRI showed hyperenhancement of myocardial tissue in 40 of 50 patients before revascularization. In all patients with hyperenhancement the difference in image intensity between hyperenhanced regions and regions without hyperenhancement was more than 6 SD. Before revascularization, 804 of the 2093 myocardial segments analyzed (38 percent) had abnormal contractility, and 694 segments (33 percent) had some areas of hyperenhancement. In an analysis of all 804 dysfunctional segments, the likelihood of improvement in regional contractility after revascularization decreased progressively as the transmural extent of hyperenhancement before revascularization increased (P<0.001). For instance, contractility increased in 256 of 329 segments (78 percent) with no hyperenhancement before revascularization, but in only 1 of 58 segments with hyperenhancement of more than 75 percent of tissue. The percentage of the left ventricle that was both dysfunctional and not hyperenhanced before revascularization was strongly related to the degree of improvement in the global mean wall-motion score (P<0.001) and the ejection fraction (P<0.001) after revascularization. Conclusions: Reversible myocardial dysfunction can be identified by contrast-enhanced MRI before coronary revascularization. (C) 2000, Massachusetts Medical Society.",
author = "Kim, {Raymond J.} and Edwin Wu and Allen Rafael and Chen, {Enn Ling} and Parker, {Michele A.} and Orlando Simonetti and Klocke, {Francis J.} and Bonow, {Robert O.} and Judd, {Robert M.}",
year = "2000",
month = "11",
day = "16",
doi = "10.1056/NEJM200011163432003",
language = "English (US)",
volume = "343",
pages = "1445--1453",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "20",

}

TY - JOUR

T1 - The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction

AU - Kim, Raymond J.

AU - Wu, Edwin

AU - Rafael, Allen

AU - Chen, Enn Ling

AU - Parker, Michele A.

AU - Simonetti, Orlando

AU - Klocke, Francis J.

AU - Bonow, Robert O.

AU - Judd, Robert M.

PY - 2000/11/16

Y1 - 2000/11/16

N2 - Background: Recent studies indicate that magnetic resonance imaging (MRI) after the administration of contrast material can be used to distinguish between reversible and irreversible myocardial ischemic injury regardless of the extent of wall motion or the age of the infarct. We hypothesized that the results of contrast-enhanced MRI can be used to predict whether regions of abnormal ventricular contraction will improve after revascularization in patients with coronary artery disease. Methods: Gadolinium-enhanced MRI was performed in 50 patients with ventricular dysfunction before they underwent surgical or percutaneous revascularization. The transmural extent of hyperenhanced regions was postulated to represent the transmural extent of non-viable myocardium. The extent of regional contractility at the same locations was determined by cine MRI before and after revascularization in 41 patients. Results: Contrast-enhanced MRI showed hyperenhancement of myocardial tissue in 40 of 50 patients before revascularization. In all patients with hyperenhancement the difference in image intensity between hyperenhanced regions and regions without hyperenhancement was more than 6 SD. Before revascularization, 804 of the 2093 myocardial segments analyzed (38 percent) had abnormal contractility, and 694 segments (33 percent) had some areas of hyperenhancement. In an analysis of all 804 dysfunctional segments, the likelihood of improvement in regional contractility after revascularization decreased progressively as the transmural extent of hyperenhancement before revascularization increased (P<0.001). For instance, contractility increased in 256 of 329 segments (78 percent) with no hyperenhancement before revascularization, but in only 1 of 58 segments with hyperenhancement of more than 75 percent of tissue. The percentage of the left ventricle that was both dysfunctional and not hyperenhanced before revascularization was strongly related to the degree of improvement in the global mean wall-motion score (P<0.001) and the ejection fraction (P<0.001) after revascularization. Conclusions: Reversible myocardial dysfunction can be identified by contrast-enhanced MRI before coronary revascularization. (C) 2000, Massachusetts Medical Society.

AB - Background: Recent studies indicate that magnetic resonance imaging (MRI) after the administration of contrast material can be used to distinguish between reversible and irreversible myocardial ischemic injury regardless of the extent of wall motion or the age of the infarct. We hypothesized that the results of contrast-enhanced MRI can be used to predict whether regions of abnormal ventricular contraction will improve after revascularization in patients with coronary artery disease. Methods: Gadolinium-enhanced MRI was performed in 50 patients with ventricular dysfunction before they underwent surgical or percutaneous revascularization. The transmural extent of hyperenhanced regions was postulated to represent the transmural extent of non-viable myocardium. The extent of regional contractility at the same locations was determined by cine MRI before and after revascularization in 41 patients. Results: Contrast-enhanced MRI showed hyperenhancement of myocardial tissue in 40 of 50 patients before revascularization. In all patients with hyperenhancement the difference in image intensity between hyperenhanced regions and regions without hyperenhancement was more than 6 SD. Before revascularization, 804 of the 2093 myocardial segments analyzed (38 percent) had abnormal contractility, and 694 segments (33 percent) had some areas of hyperenhancement. In an analysis of all 804 dysfunctional segments, the likelihood of improvement in regional contractility after revascularization decreased progressively as the transmural extent of hyperenhancement before revascularization increased (P<0.001). For instance, contractility increased in 256 of 329 segments (78 percent) with no hyperenhancement before revascularization, but in only 1 of 58 segments with hyperenhancement of more than 75 percent of tissue. The percentage of the left ventricle that was both dysfunctional and not hyperenhanced before revascularization was strongly related to the degree of improvement in the global mean wall-motion score (P<0.001) and the ejection fraction (P<0.001) after revascularization. Conclusions: Reversible myocardial dysfunction can be identified by contrast-enhanced MRI before coronary revascularization. (C) 2000, Massachusetts Medical Society.

UR - http://www.scopus.com/inward/record.url?scp=0034676602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034676602&partnerID=8YFLogxK

U2 - 10.1056/NEJM200011163432003

DO - 10.1056/NEJM200011163432003

M3 - Article

C2 - 11078769

AN - SCOPUS:0034676602

VL - 343

SP - 1445

EP - 1453

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 20

ER -